Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus target price of $26.75 for the company, according to Zacks. Zacks has also given Verona Pharma PLC American Depositary Share an industry rank of 104 out of 265 based on the ratings given to related companies.

A number of research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Verona Pharma PLC American Depositary Share in a report on Friday, September 8th.

Institutional investors have recently modified their holdings of the business. Tekla Capital Management LLC bought a new stake in Verona Pharma PLC American Depositary Share in the 2nd quarter valued at $3,211,000. Vivo Capital LLC bought a new stake in Verona Pharma PLC American Depositary Share in the 2nd quarter valued at $8,208,000. Finally, FIL Ltd bought a new stake in Verona Pharma PLC American Depositary Share in the 2nd quarter valued at $873,000. 40.27% of the stock is owned by hedge funds and other institutional investors.

Verona Pharma PLC American Depositary Share (NASDAQ VRNA) traded up $0.49 during trading hours on Tuesday, reaching $11.80. 7,714 shares of the company were exchanged, compared to its average volume of 5,677. Verona Pharma PLC American Depositary Share has a 1-year low of $10.44 and a 1-year high of $17.50.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Set $26.75 Target Price for Verona Pharma PLC American Depositary Share (VRNA)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/05/zacks-brokerages-set-26-75-target-price-for-verona-pharma-plc-american-depositary-share-vrna.html.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.